• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review
CONCLUSIONS: While the available evidence is limited, this systematic review demonstrated a positive finding of the association between warfarin adherence and anticoagulation control in patients with AF.PMID:34982455 | DOI:10.26355/eurrev_202112_27642
Source: European Review for Medical and Pharmacological Sciences - January 4, 2022 Category: Drugs & Pharmacology Authors: M Ababneh S A Nasser A Rababa'h F Ababneh Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 13, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
ConclusionsThis study demonstrated that apixaban and rivaroxaban in patients with a BMI ≥50 kg/m2 for treatment of NVAF may be safe and effective at preventing thromboembolic events and had no increased risk of bleeding. Although, findings should be interpreted with caution and confirmed with additional studies. This study contributes to the growing body of evidence that direct oral anticoagulants (DOACs) may be effective and safe to use for the treatment of NVAF in patients with BMI ≥50 kg/m2.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 25, 2021 Category: Drugs & Pharmacology Authors: Cavan P. O ’Kane, Juan Carlo O. Avalon, Jordan L. Lacoste, Wei Fang, Christopher M. Bianco, Laura Davisson, Kara L. Piechowski Tags: ORIGINAL RESEARCH ARTICLE Source Type: research